Navigation Links
Global Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
Date:12/27/2013

DUBLIN, December 27, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/3zf33c/erectile) have announced the addition of the "Global Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Erectile dysfunction (ED) is the inability to achieve or maintain satisfactory erection of penis during sexual intercourse. It is usually an age related condition but can also be triggered by psychological factors. It may occur due to various reasons such as smoking, sedentary lifestyle and administration of certain drugs such as antidepressants, psychotropic drugs, antihypertensive and recreational drugs.

Presently, oral phosphodiesterase type 5 inhibitors (PDE 5) commonly form the first line of treatment prescribed by doctors for ED. These include drugs namely, Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil) and Zydena (udenafil). The demand for erectile dysfunction drugs is high and is continuously rising as it caters to the needs of the growing elderly population and the high incidence rates of chronic disorders comprising hypertension, renal diseases and diabetes, neurological disorders and hormonal insufficiencies.

This report studies the global erectile dysfunction drugs market with a major focus on the branded drugs which include Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil) and others such as MUSE (Medicated Urethral System for Erections), Mvix and Helleva.

Pipeline analysis for drugs namely, Vitaros (alprostadil), Uprima (apomorphine) and others have also been included in the report. Market size and forecasts for the period 2010 - 2019 have been provided for each of the drugs, in terms of USD million, considering historical data for 2010 and 2011, and base year as 2012. The % compounded annual growth rate (CAGR) for each market segment for the forecast period 2013 - 2019 has also been provided along with market size estimations.

Key Topics Covered:

1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 List of Abbreviations

2 Executive Summary

3 Market Overview
3.1 Introduction to Erectile Dysfunction
3.2 Current Market Trends and Future Outlook
3.3 Types of Treatments for ED
3.4 Market Drivers
3.5 Market Restraints
3.6 Market Opportunities
3.7 Porter's Five Forces Analysis: Global Erectile Dysfunction Drugs Market
3.8 Market Attractiveness Analysis: Global Erectile Dysfunction Drugs Market, By Geography (2015)

4 Global Erectile Dysfunction Drugs Market Revenue, By Brand, 2011-2019 (USD Million)
4.1 Market Overview
4.2 Viagra (Sildenafil Citrate)
4.3 Cialis (Tadalafil)
4.4 Levitra/Staxyn (Vardenafil)
4.5 Stendra/Spedra (Avanafil)
4.6 Zydena (Udenafil)
4.7 MUSE (Medicated Urethral System for Erection)
4.8 Mvix (Mirodenafil)
4.9 Helleva (Lodenafil Carbonate)

5 Global Erectile Dysfunction Drugs Market, Pipeline Analysis
5.1 Overview
5.2 Vitaros (Alprostadil)
5.3 Uprima (Apomorphine)
5.4 Others (Topiglan, Melanocortin Activators, Gene Therapy)

6 Global Erectile Dysfunction Drugs Market, By Geography
6.1 Overview
6.2 North America
6.3 Europe
6.4 Asia-Pacific
6.5 Rest of the World (Row)

7 Competitive Landscape
7.1 Market Share Analysis: Global Erectile Dysfunction Drugs Market, 2012 (%)

8 Recommendations
8.1 Novel Drug Formulations and Genericization owing to Patent Expiration of well recognized ED Drugs
8.2 Mergers and Acquisitions to Strengthen Market Presence
8.3 Cost Containment Measures

9 Company Profiles

Companies Mentioned:

  • Apricus Biosciences, Inc
  • Bayer AG
  • Cristalia Produtos Quimicos Farmaceuticos Ltda
  • Dong-A Pharmaceutical Co Ltd
  • Eli Lilly And Company
  • Meda Pharmaceuticals, Inc
  • Pfizer, Inc
  • SK Chemicals Co Ltd
  • Vivus, Inc

For more information visit http://www.researchandmarkets.com/research/3zf33c/erectile

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
2. ConvaTec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Attendees Save Up To $800 on Global Healthcare Conferences in 2012 by Registering Through Global Information Inc.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
8. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
11. Global Pharmaceutical Leaders All Converging in Parsippany, New Jersey on September 11-12, 2012 for Breakthrough Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading ... Word(TM) Online(TM), which enables sleep physicians to create and edit their interpretation reports. ... and provides a familiar interface that does not require additional training to use. ...
(Date:4/28/2017)... Grants Pass, OR (PRWEB) , ... April 28, ... ... Adetutu Ijose, http://www.foodsthathealdaily.com , http://www.wiredlifesolutions.com , “Computers are everywhere and ... Kleyne Hour Power of Water, Global Climate Change and Your Health on Voice ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood ... to the labor and delivery team at Women’s Hospital at Renaissance in Edinburg for ... birth at the hospital and decide to donate. , “Women’s Hospital at Renaissance ...
(Date:4/28/2017)... ... ... Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a new ... not. Yisrayl says with so many titles and names for the Creator, it’s hard ... a little Scripture, backed with a lot of research, the truth is undeniable. , ...
(Date:4/28/2017)... , ... April 28, 2017 , ... NuevaCare, a leading ... diverse as Millbrae, Burlingame, and Palo Alto, is proud to announce information upgrades to ... to bookmark and read organized content on topics such as home care (generally) as ...
Breaking Medicine News(10 mins):